Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sino BiopharmaceuticalSBMFF 61 Return-on-Tangible-Asset is -3.00% as of Dec. 2025. GuruFocus rates SBMFF with a GF Score™ of 61/100 and a GF Value™ of $0.60 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,416 Biotechnology companies, Sino Biopharmaceutical ranks better than 85.03% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Sino Biopharmaceutical's annualizedNet Income for the quarter that ended in Dec. 2025 was $-297 Mil. Sino Biopharmaceutical's average total tangible assets for the quarter that ended in Dec. 2025 was $9,893 Mil. Therefore, Sino Biopharmaceutical's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was -3.00%.
The historical rank and industry rank for Sino Biopharmaceutical's Return-on-Tangible-Asset or its related term are showing as below:
SBMFF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 3.46 Med: 8.02 Max: 38.18
Current: 3.46
During the past 13 years, Sino Biopharmaceutical's highest Return-on-Tangible-Asset was 38.18%. The lowest was 3.46%. And the median was 8.02%.
SBMFF's Return-on-Tangible-Asset is ranked better than 85.03% of 1416
companies
in the Biotechnology industry
Industry Median: -35.76
vs SBMFF: 3.46
Sino Biopharmaceutical (OTCPK:SBMFF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Sino Biopharmaceutical Return-on-Tangible-Asset Related Terms
Sino Biopharmaceutical Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Sino Biopharmaceutical's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sino Biopharmaceutical Return-on-Tangible-Asset Chart
SBMFF vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Sino Biopharmaceutical's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sino Biopharmaceutical Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Sino Biopharmaceutical's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of -3.00% mean?
Sino Biopharmaceutical (SBMFF) has a Return-on-Tangible-Asset of -3.00% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Sino Biopharmaceutical and its competitors. Over the past decade, Sino Biopharmaceutical's Return-on-Tangible-Asset has ranged from 3.46 to 38.18. According to the industry distribution chart, Sino Biopharmaceutical ranks #212 out of 1416 companies in the Biotechnology industry, placing it in the top 15%.
Is Sino Biopharmaceutical's Return-on-Tangible-Asset too high?
Sino Biopharmaceutical's current Return-on-Tangible-Asset is -3.00%. Over the past 10 years, this metric has ranged from a low of 3.46 to a high of 38.18. Based on the distribution chart, Sino Biopharmaceutical ranks #212 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sino Biopharmaceutical has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sino Biopharmaceutical ranks #212 out of 1416 companies for Return-on-Tangible-Asset. This places Sino Biopharmaceutical in the top 15% of its industry — outperforming the majority of peers. Historically, Sino Biopharmaceutical's own Return-on-Tangible-Asset has ranged from 3.46 to 38.18 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Sino Biopharmaceutical and its competitors. Sino Biopharmaceutical's current Return-on-Tangible-Asset is -3.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (SBMFF) is currently considered Fairly Valued. The stock's GF Value™ is $0.60, compared to a current price of $0.64 — trading 6.2% above its estimated fair value. The current Return-on-Tangible-Asset is -3.00%. Sino Biopharmaceutical's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Sino Biopharmaceutical (SBMFF), the current Return-on-Tangible-Asset is -3.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sino Biopharmaceutical (SBMFF) Overvalued in 2026?
Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be overvalued.
The current stock price of $0.64 is trading 6.2% above its estimated GF Value™ of $0.60.
GuruFocus considers Sino Biopharmaceutical to be Fairly Valued.
Key valuation signals for SBMFF:
Return-on-Tangible-Asset: -3.00%
GF Value™: $0.60 vs. price of $0.64 (6.2% above fair value)
No single metric tells the full story. See the SBMFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
61GF Score
Get the complete analysis for SBMFF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBMFF has been successfully added to your 
